<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001428'>Somatic mutation</z:hpo> of the FLT3 gene as an internal tandem duplication (ITD) of the juxtamembrane domain-coding sequence causes constitutive tyrosine phosphorylation and activation </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e>-specific DNA has been documented in the sera of patients with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> even when it is in an early stage </plain></SENT>
<SENT sid="2" pm="."><plain>We compared the detection of FLT3 ITD in DNA extracted from cells of bone marrow (BM) <z:hpo ids='HP_0002835'>aspirations</z:hpo> with DNA extracted from peripheral blood (PB) plasma in patients newly diagnosed with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; 85 patients), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; 16 patients), and <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL; 16 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>FLT3 ITD was detected in 18 (21%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples and in one (6%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> sample in both cellular and plasma DNA but in none of the ALL samples </plain></SENT>
<SENT sid="4" pm="."><plain>Hemizygous/homozygous FLT3 ITD was detected in five (28%) of the FLT3 ITD-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> using plasma DNA, whereas only four of these cases showed hemizygous/homozygous FLT3 ITD using cellular DNA </plain></SENT>
<SENT sid="5" pm="."><plain>The presence of FLT3 ITD was associated with significantly shorter survival (P = 0.02) when only patients younger than 50 years of age (48 AML+<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients) were considered </plain></SENT>
<SENT sid="6" pm="."><plain>This finding was independent of cytogenetics in this age group </plain></SENT>
<SENT sid="7" pm="."><plain>However, patients with the FLT3 ITD hemizygous/homozygous phenotype had even shorter survival (P = &lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>As expected, the presence of FLT3 ITD correlated with higher white blood cell (WBC) counts </plain></SENT>
<SENT sid="9" pm="."><plain>These data demonstrate that plasma DNA is a reliable alternative resource for detecting FLT3ITD, especially the hemizygous/homozygous genotype </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, the data derived from this study support the notion that the presence of FLT3 ITD in conjunction with the absence of the <z:mp ids='MP_0002169'>wild-type</z:mp> FLT3 allele predicts an especially poor prognosis for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>